Average Co-Inventor Count = 4.85
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Theravance Biopharma R&d Ip, LLC (28 from 262 patents)
2. Theravance, Inc. (1 from 386 patents)
29 patents:
1. 12016835 - Neprilysin inhibitors
2. 11697648 - Fused pyrimidine pyridinone compounds as JAK inhibitors
3. 11642332 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
4. 11590116 - Substituted pyridines and methods of use
5. 11547687 - Neprilysin inhibitors
6. 11339160 - Imidazole and triazole containing bicyclic compounds as JAK inhibitors
7. 11033533 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
8. 10968205 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
9. 10851102 - Imidazole and triazole containing bicyclic compounds as JAK inhibitors
10. 10744104 - Neprilysin inhibitors
11. 10548879 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
12. 10538513 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
13. 10392368 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
14. 10172834 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
15. 10123984 - Neprilysin inhibitors